Skip to content
FDAMedicines

Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling

FDA recall n-endo-expands-voluntary-recall-clonazepam-orally-disintegrating-tablets-usp-c-iv- ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Mislabeled with the incorrect strength on the carton
Text from FDA, unedited.

The recalled product

Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to potential product carton strength mislabeling.
Text from FDA, unedited.

Company announcement, as FDA publishes it

MALVERN, PA, November 18, 2024 – Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to potential product carton strength mislabeling.

Specifically, Endo’s ongoing investigation has identified the possibility that the Clonazepam product lots listed below contain a limited number of cartons printed with the incorrect strength and National Drug Code (NDC) code due to an error by a third-party packager. The blister strips and tablets inside the product pack reflect the correct strength for the lot.

The following table details the lots being added to the voluntary recall, including lot product description and NDC number.

Risk Statement: Children and adults who inadvertently consume a higher dose of clonazepam could be at increased risk for the adverse events of significant sedation, confusion, dizziness, diminished reflexes, ataxia, and hypotonia. There is reasonable probability for significant, possibly life-threatening, respiratory depression especially for patients with concomitant pulmonary disease, patients who have prescribed dosing near maximal dosing, and patients also taking other medications that could cause additional respiratory depression.

To date, Endo has not received any reports of adverse events associated with this product recall.

Clonazepam Orally Disintegrating Tablets are indicated alone or as an adjunct in the treatment of the Lennoz-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. Additionally, the product is indicated for the treatment of panic disorder.

Package Identification:

The product is packaged in cartons containing 60 tablets packed into 10 blister strips each containing 6 tablets. The carton and each blister strip pocket are printed with the name, strength, lot number, expiration date, and NDC number. The packaging lists the legacy company Par Pharmaceutical which previously marketed clonazepam before the product was acquired by Endo.

The images below provide an example of the potential mislabeling showing the components of a package of Clonazepam Orally Disintegrating tablets, USP 2 mg lot 550176501 with a carton bearing the product description and NDC code of Clonazepam Orally Disintegrating Tablets, USP 1 mg 60-count. The location of the lot number on each component of the package is shown on the photographs below.

Action Required: The product lots were distributed through wholesale distributors to retail pharmacies nationwide.

Endo is providing written notification to wholesale accounts and retailers that have received the product lots and is arranging for the return of all existing inventory through Inmar, Inc.

Distributors, retailers that have the product lot being recalled should immediately stop distributing and dispensing and return to the place of purchase or contact Inmar on the below telephone line.

Consumers in possession of any unused prescribed tablet cartons of Clonazepam Orally Disintegrating tablets, USP bearing the above lot numbers have been advised to discontinue use of the product.

In the event that a patient inadvertently took an incorrect dose rather than the intended dose, they are advised to consult a physician.

Consumers with questions regarding this recall can contact Inmar by telephone at 877-890-0765 (Monday through Friday, 9 a.m. to 5 p.m. ET) or by email at rxrecalls@inmar.com .

For more information about Clonazepam Orally Disintegrating Tablets, USP, please see full Prescribing Information including BOXED WARNING available at DailyMed - CLONAZEPAM tablet, orally disintegrating (nih.gov) .

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online

Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

About Endo Endo is a diversified pharmaceutical company boldly transforming insights into life- enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn .

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including but not limited to any statements related to product recalls, mislabeling, adverse events, FDA or other regulatory actions and any other statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of risks, uncertainties and factors, including risks and uncertainties related to the recall and any future recalls, potential adverse events and any regulatory actions by the FDA. Endo assumes no obligation to publicly update any forward- looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with its Form S-1/A.

Media: Investors: Linda Huss Juan Avendano media.relations@endo.com investor.relations@endo.com

Text from FDA (the company’s words), unedited.
  • Clonazepam Orally Disintegrating Tablets, USP (C-IV)

    Lot or code
    Potential Product Description / NDC Number: Clonazepam ODT, USP (C-IV) 2mg / 49884-310-02; Lot #: 550176501; Expiry date: Feb 2027 | Potential Product Description / NDC Number: 550176601; Lot #: Feb 2027 | Potential Product Description / NDC Number: Clonazepam ODT, USP (C-IV) 0.125mg / 49884-306-02; Lot #: 550174101; Expiry date: Jan 2027 | Potential Product Description / NDC Number: Clonazepam ODT, USP (C-IV) 0.25mg / 49884-307-02; Lot #: 550142801; Expiry date: Aug 2026 | Potential Product Description / NDC Number: 550142901; Lot #: Aug 2026 | Potential Product Description / NDC Number: 550143001; Lot #: Aug 2026 | Potential Product Description / NDC Number: 550143101; Lot #: Aug 2026 | Potential Product Description / NDC Number: 550143201; Lot #: Aug 2026 | Potential Product Description / NDC Number: 550143301; Lot #: Aug 2026 | Potential Product Description / NDC Number: 550143401; Lot #: Aug 2026 | Potential Product Description / NDC Number: 550147201; Lot #: Aug 2026 | Potential Product Description / NDC Number: 550147401; Lot #: Aug 2026 | Potential Product Description / NDC Number: Clonazepam ODT, USP (C-IV) 1mg / 49884-309-02; Lot #: 550145201; Expiry date: Aug 2026 | Potential Product Description / NDC Number: 550175901; Lot #: Feb 2027 | Potential Product Description / NDC Number: 550176001; Lot #: Feb 2027 | Potential Product Description / NDC Number: 550176201; Lot #: Feb 2027

Source

Issued by
U.S. Food and Drug Administration
Firm
Endo, Inc.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Endo, Inc., Medicine: Clonazepam, Month: November 2024, Week 2024-W47. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Mislabeled with the incorrect strength on the carton”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on November 21, 2024.

Other notices of Endo, Inc.